ESSA Pharma
Yahoo Finance • 10 months ago
ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the 2024 ASCO Genitourinary Cancers Symposium
Combination of masofaniten plus enzalutamide continues to be well tolerated with deep and durable reductions in PSA in patients with mCRPC Phase 2 dose expansion currently underway at the RP2CDs of masofaniten 600 mg BID in combination wi... Full story
Yahoo Finance • last year
ESSA Pharma to Present at the Jefferies London Healthcare Conference
SOUTH SAN FRANCISCO, Calif. and VANCOUVER, Canada, Nov. 8, 2023 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of p... Full story
Yahoo Finance • 2 years ago
Summit Therapeutics Appoints Experienced Clinical Leader Dr. Alessandra Cesano to its Board of Directors
Menlo Park, California, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that Dr. Alessandra Cesano, MD, PhD, has been appointed to its Board of Directors, effec... Full story
Yahoo Finance • 2 years ago
ESSA Pharma to Participate in Two Upcoming Investor Conferences
SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, Nov. 10, 2022 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of pro... Full story
